119 related articles for article (PubMed ID: 29282222)
1. A KDM5 Inhibitor Increases Global H3K4 Trimethylation Occupancy and Enhances the Biological Efficacy of 5-Aza-2'-Deoxycytidine.
Leadem BR; Kagiampakis I; Wilson C; Cheung TK; Arnott D; Trojer P; Classon M; Easwaran H; Baylin SB
Cancer Res; 2018 Mar; 78(5):1127-1139. PubMed ID: 29282222
[TBL] [Abstract][Full Text] [Related]
2. Structural analysis of human KDM5B guides histone demethylase inhibitor development.
Johansson C; Velupillai S; Tumber A; Szykowska A; Hookway ES; Nowak RP; Strain-Damerell C; Gileadi C; Philpott M; Burgess-Brown N; Wu N; Kopec J; Nuzzi A; Steuber H; Egner U; Badock V; Munro S; LaThangue NB; Westaway S; Brown J; Athanasou N; Prinjha R; Brennan PE; Oppermann U
Nat Chem Biol; 2016 Jul; 12(7):539-45. PubMed ID: 27214403
[TBL] [Abstract][Full Text] [Related]
3. KDM5 family as therapeutic targets in breast cancer: Pathogenesis and therapeutic opportunities and challenges.
Li CY; Wang W; Leung CH; Yang GJ; Chen J
Mol Cancer; 2024 May; 23(1):109. PubMed ID: 38769556
[TBL] [Abstract][Full Text] [Related]
4. Studies on the Interaction of the Histone Demethylase KDM5B with Tricarboxylic Acid Cycle Intermediates.
Tarhonskaya H; Nowak RP; Johansson C; Szykowska A; Tumber A; Hancock RL; Lang P; Flashman E; Oppermann U; Schofield CJ; Kawamura A
J Mol Biol; 2017 Sep; 429(19):2895-2906. PubMed ID: 28827149
[TBL] [Abstract][Full Text] [Related]
5. 8-Substituted Pyrido[3,4-d]pyrimidin-4(3H)-one Derivatives As Potent, Cell Permeable, KDM4 (JMJD2) and KDM5 (JARID1) Histone Lysine Demethylase Inhibitors.
Bavetsias V; Lanigan RM; Ruda GF; Atrash B; McLaughlin MG; Tumber A; Mok NY; Le Bihan YV; Dempster S; Boxall KJ; Jeganathan F; Hatch SB; Savitsky P; Velupillai S; Krojer T; England KS; Sejberg J; Thai C; Donovan A; Pal A; Scozzafava G; Bennett JM; Kawamura A; Johansson C; Szykowska A; Gileadi C; Burgess-Brown NA; von Delft F; Oppermann U; Walters Z; Shipley J; Raynaud FI; Westaway SM; Prinjha RK; Fedorov O; Burke R; Schofield CJ; Westwood IM; Bountra C; Müller S; van Montfort RL; Brennan PE; Blagg J
J Med Chem; 2016 Feb; 59(4):1388-409. PubMed ID: 26741168
[TBL] [Abstract][Full Text] [Related]
6. Phosphorylation of the histone demethylase KDM5B and regulation of the phenotype of triple negative breast cancer.
Yeh IJ; Esakov E; Lathia JD; Miyagi M; Reizes O; Montano MM
Sci Rep; 2019 Nov; 9(1):17663. PubMed ID: 31776402
[TBL] [Abstract][Full Text] [Related]
7. The failure of DAC to induce OCT2 expression and its remission by hemoglobin-based nanocarriers under hypoxia in renal cell carcinoma.
Chen L; Wang Z; Xu Q; Liu Y; Chen L; Guo S; Wang H; Zeng K; Liu J; Zeng S; Yu L
Theranostics; 2020; 10(8):3562-3578. PubMed ID: 32206108
[No Abstract] [Full Text] [Related]
8. Discovery of an efficacious KDM5B PROTAC degrader GT-653 up-regulating IFN response genes in prostate cancer.
Guan T; Zhang Y; Li S; Zhang W; Song Y; Li Y; He Y; Chen Y
Eur J Med Chem; 2024 Jun; 272():116494. PubMed ID: 38749268
[TBL] [Abstract][Full Text] [Related]
9. JARID1B is a luminal lineage-driving oncogene in breast cancer.
Yamamoto S; Wu Z; Russnes HG; Takagi S; Peluffo G; Vaske C; Zhao X; Moen Vollan HK; Maruyama R; Ekram MB; Sun H; Kim JH; Carver K; Zucca M; Feng J; Almendro V; Bessarabova M; Rueda OM; Nikolsky Y; Caldas C; Liu XS; Polyak K
Cancer Cell; 2014 Jun; 25(6):762-77. PubMed ID: 24937458
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of decitabine-loaded gelatinases-stimuli nanoparticles in overcoming cancer drug resistance is mediated via its enhanced demethylating activity to transcription factor AP-2 epsilon.
Hong YD; Zhang J; Zhuang M; Li W; Wu PU; Li RT; Hu N; Bian BX; Song ZY; Wu FL
Oncotarget; 2017 Dec; 8(70):114495-114505. PubMed ID: 29383097
[TBL] [Abstract][Full Text] [Related]
11. Design, Synthesis and Characterization of Covalent KDM5 Inhibitors.
Vazquez-Rodriguez S; Wright M; Rogers CM; Cribbs AP; Velupillai S; Philpott M; Lee H; Dunford JE; Huber KVM; Robers MB; Vasta JD; Thezenas ML; Bonham S; Kessler B; Bennett J; Fedorov O; Raynaud F; Donovan A; Blagg J; Bavetsias V; Oppermann U; Bountra C; Kawamura A; Brennan PE
Angew Chem Int Ed Engl; 2019 Jan; 58(2):515-519. PubMed ID: 30431220
[TBL] [Abstract][Full Text] [Related]
12. Structural optimization of a lysine demethylase 5 inhibitor for improvement of its cellular activity.
Terao M; Yamashita Y; Takada Y; Itoh Y; Suzuki T
Bioorg Med Chem; 2024 Jan; 98():117579. PubMed ID: 38168630
[TBL] [Abstract][Full Text] [Related]
13. DNA Methylation Patterns Separate Senescence from Transformation Potential and Indicate Cancer Risk.
Xie W; Kagiampakis I; Pan L; Zhang YW; Murphy L; Tao Y; Kong X; Kang B; Xia L; Carvalho FLF; Sen S; Chiu Yen RW; Zahnow CA; Ahuja N; Baylin SB; Easwaran H
Cancer Cell; 2018 Feb; 33(2):309-321.e5. PubMed ID: 29438699
[TBL] [Abstract][Full Text] [Related]
14. Targeting histone demethylases KDM5A and KDM5B in AML cancer cells: A comparative view.
Shokri G; Doudi S; Fathi-Roudsari M; Kouhkan F; Sanati MH
Leuk Res; 2018 May; 68():105-111. PubMed ID: 29602065
[TBL] [Abstract][Full Text] [Related]
15. Biochemical Studies and Molecular Dynamic Simulations Reveal the Molecular Basis of Conformational Changes in DNA Methyltransferase-1.
Ye F; Kong X; Zhang H; Liu Y; Shao Z; Jin J; Cai Y; Zhang R; Li L; Zhang YW; Liu YC; Zhang C; Xie W; Yu K; Ding H; Zhao K; Chen S; Jiang H; Baylin SB; Luo C
ACS Chem Biol; 2018 Mar; 13(3):772-781. PubMed ID: 29381856
[TBL] [Abstract][Full Text] [Related]
16. Structure-based design and discovery of potent and selective KDM5 inhibitors.
Nie Z; Shi L; Lai C; O'Connell SM; Xu J; Stansfield RK; Hosfield DJ; Veal JM; Stafford JA
Bioorg Med Chem Lett; 2018 May; 28(9):1490-1494. PubMed ID: 29627262
[TBL] [Abstract][Full Text] [Related]
17. KDM5B overexpression predicts a poor prognosis in patients with squamous cell carcinoma of the head and neck.
Huang D; Qiu Y; Li G; Liu C; She L; Zhang D; Chen X; Zhu G; Zhang X; Tian Y; Liu Y
J Cancer; 2018; 9(1):198-204. PubMed ID: 29290786
[No Abstract] [Full Text] [Related]
18. KDM5 histone demethylases repress immune response via suppression of STING.
Wu L; Cao J; Cai WL; Lang SM; Horton JR; Jansen DJ; Liu ZZ; Chen JF; Zhang M; Mott BT; Pohida K; Rai G; Kales SC; Henderson MJ; Hu X; Jadhav A; Maloney DJ; Simeonov A; Zhu S; Iwasaki A; Hall MD; Cheng X; Shadel GS; Yan Q
PLoS Biol; 2018 Aug; 16(8):e2006134. PubMed ID: 30080846
[TBL] [Abstract][Full Text] [Related]
19. KDM5B is a master regulator of the H3K4-methylome in stem cells, development and cancer.
Xhabija B; Kidder BL
Semin Cancer Biol; 2019 Aug; 57():79-85. PubMed ID: 30448242
[TBL] [Abstract][Full Text] [Related]
20. KDM5B promotes breast cancer cell proliferation and migration via AMPK-mediated lipid metabolism reprogramming.
Zhang ZG; Zhang HS; Sun HL; Liu HY; Liu MY; Zhou Z
Exp Cell Res; 2019 Jun; 379(2):182-190. PubMed ID: 30978340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
